Modulator therapy does not appear to affect the magnitude of lung function impairment or recovery pattern during pulmonary ...

FDA lifts clinical hold following review of Company’s Complete Response submission.Company expects to restart U.S. enrollment in late 2025 or ...

Mortality rates for pneumonia and pulmonary fibrosis have declined since 1999, but disparities persist by sex, race, and ...

HealthDay News — For U.S. patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slows the decline in forced vital capacity (FVC), according to a study presented at CHEST 2025, the annual ...

Abstract: The development of scar tissue (fibrosis) in the lungs is a hallmark of pulmonary fibrosis, a progressive lung disease. impairing its ability to function properly. Progressive nature leading ...

The FDA approved nerandomilast (Jascayd) tablets for idiopathic pulmonary fibrosis (IPF), the first new product for the progressive lung condition in over a decade, the agency announced on Tuesday.

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF). This is the first new therapy in more than 10 years to be approved for ...

Tvardi Therapeutics has failed its first big test as a public company. Months after joining the Nasdaq, the biotech has reported the unappetizing mix of high dropout rates and placebolike efficacy in ...

Introduction: Dermatomyositis (DM) is a rare autoimmune disorder, with the anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody positive subtype associated with severe complications ...

Liver fibrosis, a progressive scarring of the liver tissue, represents a major global health burden with limited treatment options. It is primarily driven by the activation of hepatic stellate cells ...

Please provide your email address to receive an email when new articles are posted on . The FDA based nerandomilast’s approval on results from two trials, one of which was the FIBRONEER-IPF trial.